2000
Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging
Federle M, Chezmar J, Rubin D, Weinreb J, Freeny P, Schmiedl U, Brown J, Borrello J, Lee J, Semelka R, Mattrey R, Dachman A, Saini S, Harms S, Mitchell D, Anderson M, Halford H, Bennett W, Young S, Rifkin M, Gay S, Ballerini R, Sherwin P, Robison R. Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging. Journal Of Magnetic Resonance Imaging 2000, 12: 689-701. PMID: 11050638, DOI: 10.1002/1522-2586(200011)12:5<689::aid-jmri5>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsUnenhanced magnetic resonance imagingMagnetic resonance imagingMangafodipir trisodium injectionFinal diagnosisMulticenter phase III clinical trialContrast-enhanced computed tomography examinationPhase III clinical trialsContrast-enhanced magnetic resonance imagingInjection of MnDPDPPatient's final diagnosisHepatic magnetic resonance imagingComputed tomography examinationEnhanced magnetic resonance imagingFocal liver diseaseAdditional diagnostic informationFocal liver lesionsLiver diseaseEarly imagingMRI evaluationHepatic massClinical trialsTomography examinationIntravenous administrationPatient managementRadiologic diagnosis
1999
A multisite phase III study of the safety and efficacy of a new manganese chloride‐based gastrointestinal contrast agent for MRI of the abdomen and pelvis
Small W, DeSimone‐Macchi D, Parker J, Sukerkar A, Hahn P, Rubin D, Zelch J, Kuhlman J, Outwater E, Weinreb J, Brown J, de Lange E, Woodward P, Arildsen R, Foster G, Runge V, Aisen A, Muroff L, Thoeni R, Parisky Y, Tanenbaum L, Totterman S, Herfkens R, Knudsen J, Laster R, Duerinckx A, Stillman A, Spritzer C, Saini S, Rofsky N, Bernardino M. A multisite phase III study of the safety and efficacy of a new manganese chloride‐based gastrointestinal contrast agent for MRI of the abdomen and pelvis. Journal Of Magnetic Resonance Imaging 1999, 10: 15-24. PMID: 10398973, DOI: 10.1002/(sici)1522-2586(199907)10:1<15::aid-jmri3>3.0.co;2-x.Peer-Reviewed Original ResearchConceptsGastrointestinal contrast agentAdverse eventsSite investigatorsGastrointestinal tract side effectsPatient diagnosisBlinded readersMore adverse eventsPhase III studyInflammatory bowel diseaseGroup of patientsPeptic ulcer diseaseML of placeboT2-weighted MRI scansMultisite clinical trialContrast agentsOral contrast agentAdditional diagnostic informationPlacebo patientsOral agentsIII studyBowel diseaseUlcer diseaseGastrointestinal pathologyLaboratory changesPhysical examination